The short version of Toll-like receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-14 and is reviewed periodically as new material appears.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
== Early life and education == Otto Hahn was born in Frankfurt am Main on 8 March 1879, the youngest son of Heinrich Hahn, a prosperous glazier and founder of the Glasbau Hahn company, and Charlotte Hahn (née Giese). He had an older half-brother Karl, his mother's son from her previous marriage, and two older brothers, Heiner and Julius. The family lived above his father's workshop. The younger three boys were educated at the Klinger Oberrealschule in Frankfurt. At the age of 15, Otto began to take a special interest in chemistry, and carried out simple experiments in the laundry room of the family home. His father wanted him to study architecture, as he had built or acquired several residential and business properties, but Otto persuaded him that his ambition was to become an industrial chemist. In 1897, after passing his Abitur, Hahn began to study chemistry at Marburg University. His subsidiary subjects were mathematics, physics, mineralogy and philosophy. Hahn joined the Students' Association of Natural Sciences and Medicine, a student fraternity and a forerunner of today's Landsmannschaft Nibelungi (Coburger Convent der akademischen Landsmannschaften und Turnerschaften). He spent his third and fourth semesters at the Ludwig-Maximilians-Universität München, studying organic chemistry under Adolf von Baeyer, physical chemistry under Wilhelm Muthmann, and inorganic chemistry under Karl Andreas Hofmann. In 1901, Hahn received his doctorate at Marburg University for a dissertation entitled "On Bromine Derivates of Isoeugenol", a topic in classical organic chemistry.
=== Operating systems === AI agents have also been integrated into operating systems developed by Microsoft, Apple, ByteDance, and Google. In November 2025, Microsoft released a test software build of Windows 11 that included agents to run background tasks, with the ability to read and write personal files. In December 2025, ByteDance released Doubao, an AI agent that can be integrated into smartphone operating systems, particularly the Nubia M153 by ZTE. Several apps in China blocked or restricted the agent, citing privacy and security concerns, including WeChat, Alipay, Taobao, Pinduoduo, Ele.me, and local banks.
=== Glaucoma === As a parasympathomimetic miotic, aceclidine decreases intraocular pressure by stimulating muscarinic receptors in the eye, which constricts the pupil and opens the trabecular meshwork to facilitate aqueous humor outflow. It was used as a topical drop in the treatment of narrow-angle and open-angle glaucoma. The clinical utility of aceclidine in glaucoma is comparable to other cholinergic miotics such as pilocarpine, though aceclidine was associated with less ciliary muscle spasm and fewer accommodative disturbances. The use of aceclidine for chronic glaucoma management has declined as other therapeutic classes, such as beta-blockers and prostaglandin analogs, became available.
In nature, uranium is found as uranium-238 (99.2742%) and uranium-235 (0.7204%). Isotope separation concentrates (enriches) the fissile uranium-235 for nuclear weapons and most nuclear power plants, except for gas cooled reactors and pressurized heavy water reactors. Most neutrons released by a fissioning atom of uranium-235 must impact other uranium-235 atoms to sustain the nuclear chain reaction. The concentration and amount of uranium-235 needed to achieve this is called a 'critical mass'. To be considered 'enriched', the uranium-235 fraction should be between 3% and 5%. This process produces huge quantities of uranium that is depleted of uranium-235 and with a correspondingly increased fraction of uranium-238, called depleted uranium or 'DU'. To be considered 'depleted', the 235U concentration should be no more than 0.3%. The price of uranium has risen since 2001, so enrichment tailings containing more than 0.35% uranium-235 are being considered for re-enrichment, driving the price of depleted uranium hexafluoride above $130 per kilogram in July 2007 from $5 in 2001. The gas centrifuge process, where gaseous uranium hexafluoride (UF6) is separated by the difference in molecular weight between 235UF6 and 238UF6 using high-speed centrifuges, is the cheapest and leading enrichment process. The gaseous diffusion process had been the leading method for enrichment and was used in the Manhattan Project.
Sources: en.wikipedia.org
Further, women in Tel Abyad and Idlib city have been banned from driving by ISIS and Jabhat al-Nursa. Other countries have begun closing their borders to Syrian refugees. On 7 October 2013, Turkey built a two-meter wall on the Syrian border in the Nusaybin district where there was frequent fighting with the rebels. Then on 9 March Turkey closed a further two of its border crossings from Syria, Oncupinar and Cilvegozu, in response to the escalating violence and worries of a terrorist plot. Up until this date Turkey had accepted nearly 2 million Syrian refugees. Aid trucks are still welcome to cross the border, but it is strictly closed to individuals. The Ba'athist regime pursued practice of issuing exit visas with strict requirements. It also closed the Damascus airport frequently because of growing violence. Bans on travel were frequently used against human rights activists and their associates, often these people would not learn about their travel ban until they were prevented leaving the country. Usually no explanations are given for these travel restrictions. The government often bans members of the opposition and their families from traveling abroad, and they are targeted if they attempt to, causing opposition families to fear to attempt to leave Syria for fear of being attacked at the airport or border crossing. Though this action is illegal under international law, Syrian courts have been known to decline to interfere in matters of national security.
=== Intellectual disability === Dysfunction of Rho proteins has also been implicated in intellectual disability. Intellectual disability in some cases involves malformation of the dendritic spines, which form the post-synaptic connections between neurons. The misshapen dendritic spines can result from modulation of rho protein signaling. After the cloning of various genes implicated in X-linked intellectual disability, three genes that have effects on Rho signaling were identified, including oligophrenin-1 (a GAP protein that stimulates GTPase activity of Rac1, Cdc42, and RhoA), PAK3 (involved with the effects of Rac and Cdc42 on the actin cytoskeleton) and αPIX (a GEF that helps activate Rac1 and Cdc42). Because of the effect of Rho signaling on the actin cytoskeleton, genetic malfunctions of a rho protein could explain the irregular morphology of neuronal dendrites seen in some cases of intellectual disability.
Oxygen scavengers Time temperature indicators and digital temperature data loggers Antimicrobials Carbon dioxide controllers Microwave susceptors Moisture control: water activity, moisture vapor transmission rate, etc. Flavor enhancers Odor generators Oxygen-permeable films Oxygen generators
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.